Shakespeare Martineau has secured a six figure investment for clinical decision support system company Deontics, through the government-backed Coronavirus Future Fund scheme.
Deontics who are based in London produce highly sophisticated artificial intelligence-based software platforms and applications to support medical professionals make clinical decisions. Deontics software has for some time provided key support to cardiac specialists at the Royal Liverpool Hospital and in April 2020 they developed the first executable Covid 19 treatment pathway.
This recent investment will see the company develop its technology and access new markets around the world.
Acting on behalf of Deontics, Shakespeare Martineau’s corporate partners Adam McGiveron and Emma Bryant advised on the application and the corporate structure ahead of the investment, successfully securing a convertible loan from the Future Fund.
Adam McGiveron said, “The coronavirus Future Fund is a government backed scheme that provides matched funding of between £125,000 and £5 million and is a great opportunity for businesses to boost their income and support development and growth.
“Deontics is a truly exciting business and we were pleased to help the company secure this new investment, which will help them to take their world leading technology to a wider market.”
Deontic’s chairman James Whitticase said: “This latest investment is an important stage in the development of our business and gives us a firm foundation for the next stage of our growth.”